A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts

Mostrar outras versões (1)

Detalhes bibliográficos
Principais autores:	van Leeuwen, N, Nijpels, G, Becker, M, Deshmukh, H, Zhou, K, Stricker, B, Uitterlinden, A, Hofman, A, van 't Riet, E, Palmer, C, Guigas, B, Slagboom, P, Durrington, P, Calle, R, Neil, A, Hitman, G, Livingstone, S, Colhoun, H, Holman, R, McCarthy, M, Dekker, J, 't Hart, L, Pearson, E
Formato:	Journal article
Publicado em:	2012

Registros relacionados

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts.
por: van Leeuwen, N, et al.
Publicado em: (2012)

A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of two Dutch and two UK cohorts
por: 't Hart, L, et al.
Publicado em: (2011)

The role of ATM in response to metformin treatment and activation of AMPK.
por: Zhou, K, et al.
Publicado em: (2012)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Colhoun, H, et al.
Publicado em: (2005)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
por: Newman, C, et al.
Publicado em: (2005)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
por: Thomason, M, et al.
Publicado em: (2004)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Hitman, G, et al.
Publicado em: (2007)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
por: DeMicco, D, et al.
Publicado em: (2005)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
por: Neil, H, et al.
Publicado em: (2006)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
por: Hitman, G, et al.
Publicado em: (2005)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Colhoun, H, et al.
Publicado em: (2009)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
por: Colhoun, H, et al.
Publicado em: (2011)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Raikou, M, et al.
Publicado em: (2007)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
por: Colhoun, H, et al.
Publicado em: (2004)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
por: Betteridge, D, et al.
Publicado em: (2009)

Role of Mitochondria in the Mechanism(s) of Action of Metformin
por: Guillaume Vial, et al.
Publicado em: (2019-05-01)

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis.
por: Zhou, K, et al.
Publicado em: (2014)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.
por: Zhou, K, et al.
Publicado em: (2011)

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
por: Zhou, K, et al.
Publicado em: (2011)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
por: Charlton-Menys, V, et al.
Publicado em: (2009)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
por: Colhoun, H, et al.
Publicado em: (2002)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Charlton-Menys, V, et al.
Publicado em: (2009)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Charlton-Menys, V, et al.
Publicado em: (2009)

Heritability of variation in glycaemic response to metformin: A genome-wide complex trait analysis
por: Zhou, K, et al.
Publicado em: (2014)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
por: Raikou, M, et al.
Publicado em: (2005)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Newman, C, et al.
Publicado em: (2008)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
por: Newman, C, et al.
Publicado em: (2006)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
por: Charlton-Menys, V, et al.
Publicado em: (2009)

Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin.
por: Mahvash Zakikhani, et al.
Publicado em: (2012-01-01)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
por: Soedamah-Muthu, S, et al.
Publicado em: (2003)

Metformin and mortality. Reply to Lund SS [letter]
por: Stevens, R, et al.
Publicado em: (2013)

Metformin and mortality. Reply to Lund SS [letter].
por: Stevens, R, et al.
Publicado em: (2013)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
por: Soedamah-Muthu, S, et al.
Publicado em: (2011)

Metformin and risk of cardiovascular disease.
por: Turner, R, et al.
Publicado em: (1999)

Risk of anaemia with long-term metformin use in a community setting
por: Donnelly, L, et al.
Publicado em: (2017)

The sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes
por: Preiss, D, et al.
Publicado em: (2016)

ANALISIS TERHADAP PERLINDUNGAN HUKUM BAGI NASABAH PENGGUNA ATM (SKIMMING KARTU ATM PADA MESIN ATM BANK X)
por: , Ronald Arthur Saiya, et al.
Publicado em: (2014)

Identifying the Latitude and Longitude of ATMs in ATM Networks
por: Niloofar Haghjoo, et al.
Publicado em: (2024-06-01)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
por: Elisabet Cuyàs, et al.
Publicado em: (2019-03-01)

METFORMIN IN THE MANAGEMENT OF TYPE-2 DIABETES - REPLY
por: Holman, R, et al.
Publicado em: (1989)